Cheng I K, Ma J T, Yeh G R, Chan M K
Department of Medicine, University of Hong Kong, Queen Mary Hospital.
Int Urol Nephrol. 1990;22(3):295-303. doi: 10.1007/BF02550409.
Eighteen patients with non-insulin dependent diabetes mellitus (NIDDM), hypertension and nephropathy were randomized to receive captopril or enalapril for 6 months. Two patients with serum creatinine of greater than 400 mumol/l had to be excluded from the study because of rapidly deteriorating renal function after starting treatment. Of the remaining patients, 7 received captopril and 9 received enalapril. Blood pressure control was achieved in about 50% of patients with either drug alone. Serum creatinine and creatinine clearance were unchanged in both groups but there was a greater tendency for the former to increase in patients with higher pretreatment values. Proteinuria was reduced at 1 month only in the enalapril group which also showed a significant elevation of serum potassium after treatment. Captopril and enalapril have only a modest antihypertensive action in patients with NIDDM and nephropathy. Their use in patients with renal insufficiency must be balanced against the risk of further aggravating the deterioration of renal function.
18例非胰岛素依赖型糖尿病(NIDDM)合并高血压及肾病患者被随机分为两组,分别接受卡托普利或依那普利治疗6个月。2例血清肌酐大于400μmol/L的患者在开始治疗后因肾功能迅速恶化而不得不被排除在研究之外。在其余患者中,7例接受卡托普利治疗,9例接受依那普利治疗。单独使用任何一种药物时,约50%的患者血压得到控制。两组患者的血清肌酐和肌酐清除率均无变化,但在治疗前值较高的患者中,前者有更大的升高趋势。仅依那普利组在治疗1个月时蛋白尿减少,且治疗后血清钾显著升高。卡托普利和依那普利对NIDDM合并肾病患者仅具有适度的降压作用。在肾功能不全患者中使用它们时,必须权衡进一步加重肾功能恶化的风险。